Evidence map›Paper›PMID 40343623›Full record

ReviewTopics in current chemistry (Cham)2025

Circular RNA, A Molecule with Potential Chemistry and Applications in RNA-based Cancer Therapeutics: An Insight into Recent Advances.

Zahra Shafaghat, Safa Radmehr, Saber Saharkhiz, Amirhossein Khosrozadeh, Kimia Feiz, Ali G Alkhathami, Gholamreza Taheripak, Marzieh Ramezani Farani, Rahem Rahmati, Fatemeh Zarimeidani and 3 more

Abstract readReview
In one paragraph

Review in Topics in current chemistry (Cham), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Dual-functional nanoplatform for simultaneous degradation of circRNAJournal of Zhejiang University. Science. B · 2026
    Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Zahra ShafaghatDepartment of Immunology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Safa RadmehrThalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Saber SaharkhizDivision of Neuroscience, Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
Amirhossein KhosrozadehDepartment of Immunology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Kimia FeizBiology Department, Texas State University, San Marcos, TX, USA.
Ali G AlkhathamiDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, P. O. Box 61413, 9088, Abha, Saudi Arabia.
Gholamreza TaheripakDepartment of Biochemistry, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. taheripak.gh@iums.ac.ir.
Marzieh Ramezani FaraniDepartment of Biological Sciences and Bioengineering, Nano Bio High-Tech Materials Research Center, Inha University, 100 Inha-Ro, Michuhol-Gu, Incheon, Republic of Korea.
Rahem RahmatiStudent Research Committee, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Fatemeh ZarimeidaniStudent Research Committee, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Hassan BasserehComputational Discovery Research Group, Institute for Diabetes and Obesity, Helmholtz, Munich, Germany.
Salar BakhtiyariDepartment of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
Iraj AlipourfardInstitute of Physical Chemistry, Polish Academy of Sciences, Marcina Kasprzaka 44/52, 01-224, Warsaw, Poland. iraj.alipourfard@wum.edu.pl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-coding RNAs (ncRNAs) are functional RNA molecules that do not code for proteins. Among these, circular RNAs (circRNAs) represent a recently identified class of endogenous ncRNAs with a pivotal role in gene regulation, alongside short ncRNAs (e.g., microRNAs or miRNAs) and long non-coding RNAs (lncRNAs). CircRNAs are characterized by their single-stranded, covalently closed circular structure, which lacks polyadenylated tails and 5'-3' ends. This unique circular conformation makes them resistant to exonuclease degradation, rendering them more stable than linear RNAs, such as mRNAs in human blood cells, which highlights their potential as biomarkers. Both linear and circular RNAs are derived from pre-mRNA precursors. However, while linear RNAs are produced through conventional splicing, circRNAs are primarily formed through a process known as reverse splicing. CircRNAs can be categorized into five basic types: exon circRNAs, circular intronic RNAs, exon-intron circRNAs, intergenic circRNAs, and fusion circRNAs. These molecules have been shown to significantly influence key hallmarks of cancer, including sustained growth signaling, proliferation, angiogenesis, resistance to apoptosis, unlimited replicative potential, and metastasis. This article will delve into the biogenesis and functions of circRNAs, explore their roles in cancer, and discuss their potential applications as therapeutic options and diagnostic biomarkers.

Indexed as

NeoplasmsRNARNA, CircularHumansRNARNA, CircularBiomarkerCancerCircRNAImmunotherapyTherapeutic targets

Identifiers

PMID40343623
PMCPMC12064628

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.